GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).

It’s part of the company’s focus on eosinophil-driven diseases and ahead of that regulatory milestone I spoke with Tiffany Robinson-Smith, who’s global medical affairs lead for biologics at GSK, about eosinophils and why they’re an important element of her company’s research programmes.

In this episode of the podcast Gitte discusses telemedicine, GN Hearing’s work in this area – and the impact of COVID-19, plus her time at LEO Pharma.

The Alderley Park Discovery Podcast, produced in partnership with pharmaphorum, presents perspectives on UK and global bioscience innovation trends, with input from key experts including managing director and leader of Bruntwood SciTech’s Alderley Park Dr Kath Mackay.

Anlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.